Two consumer categories in the last twenty years have walked the same regulatory arc, in the same order, with the same supporting cast. Kratom did it between roughly 2012 and 2018. SARMs did it between roughly 2014 and 2020. Peptides are now in the middle of doing it for the third time.
The pattern is not a coincidence. It is the structural response of a small set of actors to a recurring fact pattern: a consumer category emerges in the gap between two regulatory frameworks, demand grows faster than enforcement budget, and the agency, the market, the payment rails, and the legislature each take their turn on stage in a predictable sequence.
If a reader can place the current category at the right point in the sequence, they can read off the next two years of headlines with surprising accuracy.
What does each act actually contain?
Act one is the honeymoon. The category emerges, often as a research carve-out or an importation loophole, and operates openly. Vendors are casual about labeling. The category trade press, such as it is, treats compliance as a vendor preference rather than a competitive moat. Prices are low. Cohort retention is high because nobody has been hurt visibly enough to break the social-proof loop. The honeymoon lasts somewhere between four and eight years depending on how visible the harm tail is. For SARMs the honeymoon ran from roughly 2010 to 2014. For kratom it ran from 2007 to 2012. For peptides the honeymoon ran from roughly 2018 to 2023.
Act two is soft enforcement. The agency starts to act, but narrowly. The first warning letters target a small number of vendors with the most aggressive marketing and the clearest violations of existing rules. Doctrine is articulated in narrow product-specific terms. The agency is using the warning-letter regime to teach the market what compliant labeling looks like. Compliant vendors quietly relabel. Non-compliant vendors discount the warnings as cheap talk and continue. The press writes a few stories. The payment processors are still neutral. The legislature is not yet involved. SARMs reached act two in 2014. Kratom in 2012. Peptides in 2023, and the recent acceleration in warning-letter cadence is the strongest dating evidence for where the act ends.
Act three is hard enforcement. This is the act that scares operators. The warning-letter language broadens from product-specific to category-level. New letters cite older letters in a way that reads as the assembly of a public doctrine. The agency files a small number of injunction cases that establish the doctrine in court. Once the doctrine is on the record, the payment processors notice. Their merchant-category-code teams reclassify vendors in the category as high risk. Reserves climb. Processor exits begin. Customs widens its inspection categories at the major import ports. Retail chains that had been carrying the category quietly relabel or delist. The category does not disappear, but the cost of operating in it triples inside eighteen months.
Act four is settlement. The market splits. A licensed pharmacy lane emerges, with higher prices and documented chain of custody, often serving a clinical audience under medical oversight. A persistent gray lane continues at smaller scale, serving the price-sensitive audience that the licensed lane cannot reach. The split is permanent in both directions: the licensed lane cannot capture the gray lane because its compliance cost is structural, and the gray lane cannot capture the licensed lane because its risk profile is unacceptable to the clinical buyer. Kratom is currently in act four with an unusual wrinkle: state-level Kratom Consumer Protection Acts have created a third lane in roughly half the states, a regulated-retail lane that sits between the other two.
What signals telegraph each transition?
The cleanest signal is linguistic. Agency enforcement letters in act two use vendor-specific and product-specific language. The agency names the misbranding, names the molecule, names the marketing claim. The legal doctrine cited is narrow.
In act three the language changes. Letters start to refer to "the category" as a whole. They cite prior letters in their own footnotes. They use a doctrinal phrase like "essentially a copy" or "a class of products," signaling that the agency is now litigating at the category level rather than the vendor level. The transition is usually visible in retrospect within a single quarter, and the careful reader can spot it close to the moment by tracking month-over-month letter cadence and the citation density inside each letter.
The second signal is payment-rail behavior. Card-not-present merchants in the affected category begin to see reserves climb. Two or three processors exit. The trade-press story is usually framed as a vendor-level decision, but the cluster timing is the tell.
The third signal is the appearance of a state-level model bill. Once the legislature can copy a template from another jurisdiction, the political cost of acting drops sharply. Kratom Consumer Protection Acts are the recent worked example: the first one passed in Arizona in 2019, and once the language existed the bill spread through another two dozen states inside three years.
The fourth signal is a retail-chain shelf shift. Retail chains have legal and reputational teams that read the same warning letters the operators do. When the chains start moving products to a different aisle, behind a counter, or off the shelf entirely, they have read the doctrine and decided.
A careful observer who tracks the four signals together can place a category in the act with high confidence. Peptides as of early 2026 show all four act-two indicators saturating: warning-letter cadence rose sharply in the second half of 2024, the citation density inside the letters has been climbing through 2025, payment-processor reserves on adjacent merchants have begun to widen, and the first state-level inquiry letters have started circulating. The fifth indicator, retail-chain shelf shift, has not yet occurred at meaningful scale. When it does, act three has begun.
What does this mean for someone buying or selling in the category now?
For a buyer, the operational implication is concrete. Vendors that are not building licensed-lane infrastructure now will not survive act three. The licensed-lane infrastructure is expensive: real chain-of-custody documentation, lot-level lab attestation from an ISO 17025 partner, a published refund and dispute policy that names a real recourse, a registered place of business with a working complaint channel. A vendor without these in early 2026 is a vendor whose cost structure cannot absorb act three.
For a seller, the implication is sharper. The act-two window is the cheapest moment to acquire the credentials that act three will price into the market. Operators who wait until the doctrine has crystallized in court will be paying the act-three rate, against a market that has already split.
For a third-party witness, the implication is the simplest of all. The category is asking for a registry that records, in public, who is operating to which standard. The signal is durable because the demand for it is structural: each act produces a deeper need for it, and act four cannot reach a stable equilibrium without one.
The pattern is not a guess. It has been performed twice in the last twenty years, and the curtain on act three is already moving.